Date published: 2026-3-31

1-800-457-3801

SCBT Portrait Logo
Seach Input

TTMP_BC030499 Inhibitors

TTMP_BC030499 inhibitors are chemical compounds that exert their inhibitory effects through the modulation of specific signaling pathways. Staurosporine, a broad-spectrum kinase inhibitor, impedes TTMP_BC030499 activity by interfering with the phosphorylation of key proteins, which could be crucial for TTMP_BC030499 signaling. Similarly, LY 294002 and Wortmannin, both PI3K inhibitors, attenuate PI3K pathway signaling, leading to a reduction in the phosphorylation state of proteins associated with TTMP_BC030499, causing a functional downturn in TTMP_BC030499. Rapamycin targets mTOR within the PI3K/AKT/mTOR pathway, hampering the phosphorylation of proteins that either regulate or are regulated by TTMP_BC030499, thus diminishing its activity. MEK inhibitors such as U0126 and PD 98059 disrupt the MAPK/ERK pathway, which, if associated with TTMP_BC030499, results in its functional inhibition. SB 203580's inhibition of p38 MAPK may similarly reduce TTMP_BC030499 activity if it operates downstream or is influencedby this signaling node. SP600125 acts as a JNK pathway inhibitor, which could attenuate TTMP_BC030499's activity by impinging on JNK-mediated signaling mechanisms.

Dasatinib, by inhibiting Src family kinases, has the potential to disrupt signaling cascades that modulate TTMP_BC030499's activity, leading to its functional suppression. Bortezomib, through proteasome inhibition, blocks NF-κB signaling, which can diminish TTMP_BC030499's activity if it is regulated by this pathway. Imatinib, which targets BCR-ABL tyrosine kinase as well as c-Kit and PDGFR, could hinder pathways that activate TTMP_BC030499, thereby reducing its activity. Lastly, Sorafenib, by targeting RAF kinases, suppresses the MAPK/ERK pathway, which would result in the inhibition of TTMP_BC030499 if it is a part of or influenced by this signaling cascade. Collectively, these inhibitors leverage their impacts on critical kinases and signaling pathways to achieve a coordinated downregulation of TTMP_BC030499's functional activity.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$153.00
$396.00
113
(4)

Staurosporine is a potent kinase inhibitor that indirectly inhibits TTMP_BC030499 by blocking the phosphorylation of proteins that may be required for TTMP_BC030499 signaling or activity.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY 294002 is a PI3K inhibitor that leads to decreased PI3K pathway signaling. The inhibition of this pathway can decrease the phosphorylation status of TTMP_BC030499 or its associated signaling proteins, leading to its functional inhibition.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Rapamycin inhibits mTOR, which is part of the PI3K/AKT/mTOR pathway. This inhibition may reduce the phosphorylation and activation of proteins downstream or upstream of TTMP_BC030499, thereby reducing its functional activity.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$64.00
$246.00
136
(2)

U0126 is a MEK inhibitor that impairs the MAPK/ERK signaling pathway. Inhibition of this pathway could lead to reduced activity of TTMP_BC030499 if it is involved in signaling through MAPK/ERK.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB 203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK, it could diminish the activity of TTMP_BC030499 if TTMP_BC030499 is downstream of or modulated by p38 MAPK signaling.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Wortmannin is another PI3K inhibitor that can decrease AKT phosphorylation, potentially leading to reduced activity of TTMP_BC030499 if it is dependent on PI3K/AKT signaling.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

PD 98059 selectively inhibits MEK, which is involved in the MAPK/ERK pathway. This could lead to diminished activity of TTMP_BC030499 if it is regulated by the MAPK/ERK pathway.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). If TTMP_BC030499 is modulated by JNK signaling, inhibition by SP600125 would lead to a decrease in TTMP_BC030499 activity.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Dasatinib is a tyrosine kinase inhibitor that can inhibit Src family kinases. If TTMP_BC030499 activity is dependent on Src kinase signaling, dasatinib would lead to its functional inhibition.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Bortezomib is a proteasome inhibitor that can prevent the degradation of IκB, thereby inhibiting NF-κB signaling. If TTMP_BC030499 is regulated by NF-κB, bortezomib would decrease its activity.